Related Experiment Video
Updated: Jan 14, 2026

Identification and Quantification of Deranged Metabolites in Critically Ill Patients Using NMR-Based Metabolomics
Published on: November 29, 2024
Metabolomics of Sepsis and Acute Kidney Injury in Infants and Children: Current Challenges in Prevention, Diagnosis,
Vanda Koko1, Vy Nguyen1, Sean N Avedissian2
1Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, 9500 Gilman Drive, MC 0657, La Jolla, CA, 92093-0657, USA.
Insights
Metabolomics aids in diagnosing sepsis and acute kidney injury (AKI) in children by identifying biomarkers. This approach can improve drug therapy and patient outcomes, though more research is needed for clinical use.
Area of Science:
- Biochemistry
- Pediatric Medicine
- Clinical Diagnostics
Background:
- Sepsis and acute kidney injury (AKI) are major causes of illness and death in children.
- Diagnosing sepsis and AKI in pediatric populations presents significant challenges.
Purpose of the Study:
- To review the application of metabolomics in diagnosing sepsis and AKI in neonates, infants, and children.
- To explore the role of metabolomic profiling in identifying disease biomarkers and optimizing drug therapy.
- To address challenges in translating metabolomic research into clinical practice.
Main Methods:
- Comprehensive literature review of metabolomics applications in pediatric sepsis and AKI.
- Analysis of studies on metabolomic profiling for biomarker discovery.
- Examination of pharmacometabolomics for drug therapy optimization.
Main Results:
- Metabolomic profiling can accurately identify biomarkers for sepsis and AKI, enabling early detection and prevention.
- Pharmacometabolomics offers potential for tailoring drug therapy by predicting pharmacokinetic profiles.
- Significant obstacles exist, including the need for standardized methods, age-specific data, and large-scale validation.
Conclusions:
- Metabolomics holds promise for improving the diagnosis and treatment of sepsis-associated AKI in children.
- Further research and standardization are crucial for integrating metabolomics into clinical practice.
- Metabolomics-driven guidelines can lead to better clinical outcomes for affected pediatric patients.
Abstract:
Sepsis and acute kidney injury (AKI) are significant contributors to morbidity and mortality in neonates, infants, and children. This comprehensive review aimed to evaluate the application of metabolomics in the challenging diagnostic process of sepsis and AKI in neonatal and pediatric populations. We highlighted the role of metabolomic profiling in enabling the accurate identification of biomarkers associated with sepsis and AKI, allowing for the timely prevention or detection of the disease. Additionally, pharmacometabolomics was presented to ascertain the contribution of metabolomics towards optimizing an individual's drug therapy via direct measurement and monitoring of drug metabolites to predict the pharmacokinetic profiles of drug compounds. This review also addressed the obstacles in translating metabolomic research into clinical practice, including the need for standardized methodologies, age-specific reference data, and large-scale validation studies as a result of the current limited literature in this area. Ultimately, the review showcased how utilizing metabolomics-driven diagnostic and treatment guidelines can promote positive clinical outcomes in infants and children affected by sepsis-associated AKI.
Related Concept Videos
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Acute Kidney Injury I: Introduction
Acute Kidney Injury II: Pathophysiology
Pharmacokinetics in Pediatric Patients: Drug Metabolism
Acute Kidney Injury III: Clinical Manifestations
Acute Kidney Injury V: Interprofessional Care

